Lack of proper tools hampers early diagnosis and treatment of antigen-specific autoimmune diseases. A new strategy that makes use of peptide-MHC reagents could control recent-onset diabetes in mice.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Casares, S. et al. Nature Immunol., 3, 385–393 (2002).
Sharma, S. D. et al. Proc. Natl Acad. Sci. USA 88, 11465–11469 (1991).
Spack, E. G. et al. J. Autoimmun. 8, 787–807 (1995).
Amrani, A. et al. Nature 406, 739–742 (2000).
Yu, L. et al. Proc. Natl Acad. Sci. USA 97, 1701–1706 (2000).
Daniel, D. et al. Eur. J. Immunol. 25, 1056–1062 (1995).
Lee, K. H. et al. Nature Immunology 2, 501–507 (2001).
Abiru, N. et al. Diabetes 50, 1274–1281 (2001).
Novak, E. J. et al. J. Clin. Invest. 104, R63–R67 (1999).
Kwok, W. W. et al. J. Immunol. 164, 4244–4249 (2000).
Meyer, A. L. et al. Proc. Natl Acad. Sci. USA 97, 11433–11438 (2000).
Quarsten, H. et al. 167, 4861–4868 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Eisenbarth, G., Nepom, G. Class II peptide multimers: promise for type 1A diabetes?. Nat Immunol 3, 344–345 (2002). https://doi.org/10.1038/ni0402-344
Issue Date:
DOI: https://doi.org/10.1038/ni0402-344